SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/54B3C92A1675F4B1BB753186D64FDA55E73DCD3D2C8AC4770B83CDCF185B223E5B471EC2F861B783AC84CCBD9B6051EE>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/54B3C92A1675F4B1BB753186D64FDA55E73DCD3D2C8AC4770B83CDCF185B223E5B471EC2F861B783AC84CCBD9B6051EE
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/54B3C92A1675F4B1BB753186D64FDA55E73DCD3D2C8AC4770B83CDCF185B223E5B471EC2F861B783AC84CCBD9B6051EE
http://www.w3.org/2000/01/rdf-schema#comment
"Findings indicate that depletion of REV3 not only can amend cisplatin-based cancer therapy but also can be applied for susceptible cancers as a potential monotherapy."
xsd:string
http://purl.uniprot.org/uniprot/#_01F887D342CB82D12100018E40312103D31CDCE6FBE8E776EA2A097840E1D520499F193175B5B144AF34F9CF14386A85
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/54B3C92A1675F4B1BB753186D64FDA55E73DCD3D2C8AC4770B83CDCF185B223E5B471EC2F861B783AC84CCBD9B6051EE
http://purl.uniprot.org/uniprot/O60673
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/54B3C92A1675F4B1BB753186D64FDA55E73DCD3D2C8AC4770B83CDCF185B223E5B471EC2F861B783AC84CCBD9B6051EE
http://purl.uniprot.org/uniprot/#_O60673-mappedCitation-22028621
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/54B3C92A1675F4B1BB753186D64FDA55E73DCD3D2C8AC4770B83CDCF185B223E5B471EC2F861B783AC84CCBD9B6051EE